Intellia Therapeutics (NASDAQ:NTLA) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Intellia Therapeutics (NASDAQ:NTLA) posted its earnings results on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.16, Briefing.com reports. The firm had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.Intellia Therapeutics’s revenue was up 78.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.27) EPS.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• The company expects a pivotal readout for lonvo-z by mid‑year with a planned BLA submission in the second half of the year, positioning it as potentially the world’s first pivotal in vivo CRISPR gene‑editing readout.
• Commercial preparations for lonvo-z are underway—field medical hires, payer engagement, validated CMC/commercial manufacturing, and market research showing very high patient and HCP interest—which the company says could enable a launch and meaningful revenue that materially reduces future capital needs.
• The nex‑z ATTR program remains disrupted by a clinical hold on the MAGNITUDE cardiomyopathy trial following liver enzyme elevations and a patient death; MAGNITUDE‑2 (polyneuropathy) was reopened with added liver monitoring, steroid‑trigger guidance, and tighter screening, while MAGNITUDE is still under active FDA discussion.
• Financials show cash, cash equivalents, and marketable securities of $605.1 million at year‑end (down from $861.7M), which management says should fund operations into H2 2027 and support key milestones despite a Q4 net loss of $95.8M.

Intellia Therapeutics Price Performance

Shares of NTLA traded up $0.86 during mid-day trading on Thursday, reaching $14.28. The company’s stock had a trading volume of 4,890,264 shares, compared to its average volume of 3,275,201. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25. The stock has a market cap of $1.65 billion, a PE ratio of -3.34 and a beta of 2.10. The company’s 50 day moving average is $11.80 and its 200 day moving average is $13.00.

Analyst Upgrades and Downgrades

NTLA has been the topic of several research reports. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Wedbush dropped their price target on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Finally, Truist Financial reiterated a “buy” rating and issued a $14.00 price objective (down from $25.00) on shares of Intellia Therapeutics in a research note on Monday, November 10th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $17.48.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 beat — Intellia reported a narrower-than-expected loss (EPS -$0.83 vs. -$0.99 est.) and revenue of $23.02M (well above estimates), with revenue up ~78% year-over-year; that earnings surprise is a key catalyst for the stock. Intellia Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Strong cash runway — Intellia ended 2025 with approximately $605M in cash, providing runway to advance multiple programs and de-risk near-term milestones. This cash position supports R&D and commercial preparation. Q4 & Full-Year 2025 Financial Results
• Positive Sentiment: Clear near-term commercial path for lonvo‑z — Management guided to HAELO Phase 3 data by mid‑2026, a potential BLA submission in 2H‑2026 and U.S. launch in 1H‑2027, which could materially re-rate the company if successful. Business Updates & Timelines
• Neutral Sentiment: Management tone and strategic updates from the earnings call emphasized clinical progress, commercial readiness and long-term CRISPR strategy—helpful context but dependent on upcoming data and approvals. Earnings Call Transcript
• Negative Sentiment: Regulatory risk: an FDA clinical hold remains for the MAGNITUDE Phase 3 trial of nex‑z in ATTR‑CM; management is engaging FDA but resolution timing is uncertain and could delay or impair that program’s value. Earnings Call Highlights & Regulatory Update
• Negative Sentiment: Profitability risk: despite the quarter-over-quarter improvement, Intellia remains unprofitable with large negative margins and analyst forecasts calling for steep net losses ahead, leaving the stock sensitive to R&D setbacks or slower-than-expected commercial progress. Zacks Q4 Coverage

Insider Buying and Selling

In related news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP James Basta sold 10,397 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. This represents a 9.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,051 shares of company stock worth $488,600 over the last 90 days. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. Ameriprise Financial Inc. grew its holdings in shares of Intellia Therapeutics by 13.9% during the second quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock worth $111,000 after purchasing an additional 1,443 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $98,000. First Trust Advisors LP acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $96,000. Amundi purchased a new position in Intellia Therapeutics during the 4th quarter worth approximately $91,000. Finally, Insigneo Advisory Services LLC purchased a new position in Intellia Therapeutics during the 4th quarter worth approximately $90,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.